Doxorubicin-associated Cardiac Remodeling Followed by CMR in Breast Cancer Patients

NACompletedINTERVENTIONAL
Enrollment

27

Participants

Timeline

Start Date

July 31, 2012

Primary Completion Date

January 31, 2015

Study Completion Date

July 31, 2016

Conditions
Breast Cancer FemaleDoxorubicin Induced Cardiomyopathy
Interventions
DRUG

Doxorubicin

Patients had prescribed endovenous doxorubicin as part of their chemotherapy regimen (mean cumulative dose 102,66 mg/m2, administered in 4 doses with 21 days interval).

DEVICE

Achieva, Philips Medical Systems (3T magnet)

Patients were imaged in supine position in a 3T magnet (Achieva, Philips Medical Systems, Best, The Netherlands). The protocol consisted of electrocardiographically gated cine imaging with steady state free-precession to assess left ventricular (LV) ejection fraction and LV mass. For imaging of late gadolinium-DTPA enhancement (LGE) we used an inversion-recovery-prepared, gradient-echo sequence with segmented acquisition, which was triggered every other heartbeat. LGE images were acquired during end-expiratory breath-holding, after administration of Dotarem. T1 was performed with a Look-Locker sequence with a non-slice-selective adiabatic inversion pulse, followed by segmented gradient-echo acquisition for 17 times after inversion, covering approximately two cardiac cycles. T1 imaging was repeated in the same LV short-axis slice, once before and five to seven times after the injection of gadolinium to cover an approximately 30-min period of slow contrast clearance.

DRUG

Gadoterate Meglumine

LGE images were acquired starting within 10 min after bolus administration of a cumulative dose of 0.2 mmol/Kg of gadoterate meglumine (Dotarem, Guerbet, Aulnay-sous-Bois, France).

Trial Locations (1)

13083-887

State University of Campinas, Campinas

All Listed Sponsors
collaborator

Fundação de Amparo à Pesquisa do Estado de São Paulo

OTHER_GOV

lead

University of Campinas, Brazil

OTHER

NCT03000036 - Doxorubicin-associated Cardiac Remodeling Followed by CMR in Breast Cancer Patients | Biotech Hunter | Biotech Hunter